Floatz logo

bp1001-a

Fallopian Tube Neoplasms

Bio-Path Holdings, Inc.nucleic_acidPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

14 Active assets in the Fallopian Tube Neoplasms cohort.

Asset / SponsorPhaseRating
Inno-206
Eli Lilly and Company
Phase 3BB
Carboplatin
Eli Lilly and Company
Phase 3BB
Sofetabart Mipitecan
Eli Lilly and Company
Phase 3B
Mirvetuximab Soravtansine
Eli Lilly and Company
Phase 3B
Pembrolizumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 3B

View all 39 →

Same molecule, other indications

bp1001-a is also rated in:

ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
peritoneum cancerDormant
CC
Indicative ·
41 / 100
View asset →
Solid Tumor, AdultDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →